You are here: Home » International » News » Others
Business Standard

Sputnik V Covid vaccine: WHO in talks with Russian institute, says report

Russia's Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country's sovereign wealth fund said on Wednesday

Topics
Russia | Coronavirus Vaccine | World Health Organization

Reuters  |  GENEVA 

Covid vaccine

GENEVA (Reuters) - The (WHO) is in discussions with the Russian institute that developed the Sputnik V candidate vaccine against COVID-19 over its potential application for emergency use listing, the U.N. agency said on Thursday.

Russia's Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country's sovereign wealth fund said on Wednesday.

The WHO, in a statement to Reuters, said: "WHO has been in touch with the Gamaleya Research Institute of Epidemiology and Microbiology, who expressed interest in applying for WHO emergency use listing.

"We look forward to receiving the data for their Sputnik V candidate vaccine. If a product submitted for assessment is found to meet the criteria for listing, WHO will publish the results widely," it said.

By granting the vaccine emergency use listing, the WHO would effectively be recommending its use to member states. The procedure streamlines the process by which new and unlicensed vaccines and other products can be used during emergencies.

The WHO, which is backing accelerated development of vaccines to stem the pandemic, has not yet prequalified any experimental vaccine nor issued an emergency use listing.

Russia's results are only the second from a late-stage human trial, following on swiftly from data released on Monday by Pfizer Inc and BioNTech which said their shot was also more than 90% effective.

 

 

(Reporting by Stephanie Nebehay; Editing by Gareth Jones and Alexandra Hudson)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 12 2020. 21:31 IST
RECOMMENDED FOR YOU
.